GoAI
Get started
BioHarvest Sciences Inc. logo

BioHarvest Sciences Inc.

BHST

NASDAQIndustrialsAgricultural - Commodities/Milling

Open in GoAI

Previous close

$2.055

+$0.015 · +0.74%

Aug 21, 4:00 PM ET

BHST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

73

Undervalued

Momentum

17

Strong Down

Sentiment

38

Bearish

Risk resilience

26

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.

Industry
Agricultural - Commodities/Milling
Sector
Industrials
Headquarters
CA
CEO
Zaki Rakib
Listed since
Jan 8, 2021
Employees
89

Market position

Day range

Current $2.055

52-week range

Current $2.055

Open
$2.075
Previous close
$2.04
Volume
9.2K
0.21× average
Average volume
44.16K
Average daily volume
Market cap
35.61M USD
Beta
1.37
Market reference 1
50-day average
$2.5609
-19.75% below average
200-day average
$4.323
-52.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
86.63M USD
P/E (TTM)
-3.81×
P/B (TTM)
2.36×
P/S (TTM)
1×
EV / EBITDA
-12.91×
Earnings yield
-11.65%
Free cash flow yield
-10.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.95%
Operating margin
-17.99%
Net margin
-31.21%
Return on equity
-43.76%
Return on assets
-23.36%
Return on invested capital
-13.42%

Financial health

Debt / equity
0.89×
Current ratio
3.97×
Altman Z-score
-2.2
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends112%-99%-309%-520%Gross margin, FY2021: 31.87%Gross margin, FY2022: 22.17%Gross margin, FY2023: 44.45%Gross margin, FY2024: 55.35%Gross margin, FY2025: 59.34%Operating margin, FY2021: -403.95%Operating margin, FY2022: -193.02%Operating margin, FY2023: -78.65%Operating margin, FY2024: -27.75%Operating margin, FY2025: -16.16%Net margin, FY2021: -467.51%Net margin, FY2022: -204.37%Net margin, FY2023: -99.15%Net margin, FY2024: -51.27%Net margin, FY2025: -32.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 31.87%. Gross margin FY2022 22.17%. Gross margin FY2023 44.45%. Gross margin FY2024 55.35%. Gross margin FY2025 59.34%. Operating margin FY2021 -403.95%. Operating margin FY2022 -193.02%. Operating margin FY2023 -78.65%. Operating margin FY2024 -27.75%. Operating margin FY2025 -16.16%. Net margin FY2021 -467.51%. Net margin FY2022 -204.37%. Net margin FY2023 -99.15%. Net margin FY2024 -51.27%. Net margin FY2025 -32.27%.

Income trends

Revenue

34.51M USD+37.00%

Operating income

−5.58M USD+20.23%

Net income

−11.14M USD+13.77%
Income trends across reported periods39.25M USD20.28M USD1.31M USD−17.66M USDRevenue, FY2021: 2.1M USDRevenue, FY2022: 5.5M USDRevenue, FY2023: 12.67M USDRevenue, FY2024: 25.19M USDRevenue, FY2025: 34.51M USDOperating income, FY2021: −8.49M USDOperating income, FY2022: −10.61M USDOperating income, FY2023: −9.97M USDOperating income, FY2024: −6.99M USDOperating income, FY2025: −5.58M USDNet income, FY2021: −9.83M USDNet income, FY2022: −11.24M USDNet income, FY2023: −12.56M USDNet income, FY2024: −12.91M USDNet income, FY2025: −11.14M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.1M USD. Revenue FY2022 5.5M USD. Revenue FY2023 12.67M USD. Revenue FY2024 25.19M USD. Revenue FY2025 34.51M USD. Operating income FY2021 −8.49M USD. Operating income FY2022 −10.61M USD. Operating income FY2023 −9.97M USD. Operating income FY2024 −6.99M USD. Operating income FY2025 −5.58M USD. Net income FY2021 −9.83M USD. Net income FY2022 −11.24M USD. Net income FY2023 −12.56M USD. Net income FY2024 −12.91M USD. Net income FY2025 −11.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue34.51M USD25.19M USD12.67M USD5.5M USD2.1M USD
Cost of goods sold14.03M USD11.25M USD7.04M USD4.28M USD1.43M USD
Gross profit20.48M USD13.94M USD5.63M USD1.22M USD670K USD
Research and development5.31M USD4.8M USD3.37M USD2.31M USD4.13M USD
Selling, general, and administrative19.14M USD14.67M USD12.08M USD9.35M USD4.76M USD
Operating expenses26.05M USD20.93M USD15.6M USD11.83M USD9.16M USD
Interest income54K USD————
Interest expense2.72M USD1.93M USD1.96M USD1.4M USD805K USD
Depreciation and amortization1.62M USD1.25M USD840K USD712K USD385.58K USD
Operating income−5.58M USD−6.99M USD−9.97M USD−10.61M USD−8.49M USD
Net income−11.14M USD−12.91M USD−12.56M USD−11.24M USD−9.83M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
44%
4 beats, 4 misses, 1 met estimate
Average EPS surprise
-35.24%
9 comparable reports
Latest EPS result
-0.17
Estimate -0.13 · Miss by 30.77%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.15-0.21-0.28Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MetQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.17, estimate -0.12, surprise -41.67%, Miss. Q2 2025, reported May 15, 2025: actual -0.13, estimate -0.15, surprise +13.33%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.24, estimate -0.11, surprise -118.18%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.14, estimate -0.14, surprise 0.00%, Met estimate. Q1 2026, reported Mar 31, 2026: actual -0.1, estimate -0.105, surprise +4.76%, Beat. Q2 2026, reported May 14, 2026: actual -0.11, estimate -0.13, surprise +15.38%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.17, estimate -0.13, surprise -30.77%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.83M8.84M7.85M6.86MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 7.28M USD, estimate 7.24M USD, surprise +0.55%, Beat. Q2 2025, reported May 15, 2025: actual 7.84M USD, estimate 8.53M USD, surprise -8.17%, Miss. Q3 2025, reported Aug 11, 2025: actual 8.52M USD, estimate 8.53M USD, surprise -0.21%, Miss. Q4 2025, reported Nov 13, 2025: actual 9.07M USD, estimate 9.16M USD, surprise -1.00%, Miss. Q1 2026, reported Mar 31, 2026: actual 9.1M USD, estimate 9.24M USD, surprise -1.50%, Miss. Q2 2026, reported May 14, 2026: actual 8.51M USD, estimate 8.5M USD, surprise +0.08%, Beat. Q3 2026, reported Aug 11, 2026: actual 8.84M USD, estimate 9.45M USD, surprise -6.50%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 9.31M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.00

143.31% upside
Past 12 months12-month forecastHigh $5.00Average $5.00Low $5.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Roth CapitalmaintainBuy
Maxim GroupmaintainBuy

BHST news

seekingalpha.com

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract…

Read source
proactiveinvestors.com

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up…

Read source
zacks.com

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.

Read source
newsfilecorp.com

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO…

Read source
newsfilecorp.com

BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance

Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional collaborations in the…

Read source

BHST peers

Space Exploration Technologies Corp. logo

SPCX

Space Exploration Technologies Corp.

$136.97

+2.22%

CSX Corporation logo

CSX

CSX Corporation

$51.59

+1.22%

Cintas Corporation logo

CTAS

Cintas Corporation

$203.79

+0.13%

PACCAR Inc logo

PCAR

PACCAR Inc

$131.03

+1.62%

Honeywell International Inc. logo

HON

Honeywell International Inc.

$215.9

-1.11%

Fastenal Company logo

FAST

Fastenal Company

$51.26

+1.18%

Continue in GoAI

Research BHST

research.disclaimer